Zealand Pharma — April 2024
-
.....Zealand has made the following awards in its long-term incentive plan. It has awarded:
20,497 restricted stock units ("RSUs") to Zealand's Board of Directors
52,777 performance stock units ("PSUs") and 52,777 RSUs have been awarded to Zealand’s Corporate Management
7,071 RSUs have been awarded to Zealand's US employees and
146,260 warrants have been awarded to Zealand's employees in Denmark (except for members of Corporate Management)... -
...With regards to the 2024 RSU grants to the Board of Directors, RSUs will vest annually in equal tranches over three years (from April 19, 2024, to April 19, 2027). For any given financial year, the total number of RSUs granted to any member of the Board of Directors cannot exceed 8,000 RSUs, and at the time of grant the total value of RSUs granted to the Chairperson of the Board cannot exceed an amount of DKK 3 million.
-
For Board members serving on a committee (other than the Chairperson of the Board), the total value cannot exceed DKK 1.5 million and for other Board members not serving on a committee, the total value cannot exceed DKK 600,000. Each vested RSU entitles the holder to receive one share in Zealand at no cost subject to certain conditions that include the Board member's continued service on the Board of Directors (or Board Committee where relevant) for the full term of being elected....
-
Hele meddelelsen findes her: https://www.zealandpharma.com/media/zealand-news/
-
"Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons". Denne meddelelse findes også på link 18.03.
-
Er det en rettighed til at købe til kurs 598? Eller hvordan er det skruet sammen?
-
De går ikke i små sko, i ZP. Fra med.nr 22: The total cost of the incentive grants is DKK 122.458.942 million. Det er da vist voldsomt mange milliarder
Det sidste med million skulle vist ikke have været med 
-
Men. bortset fra det - såp tyder det på, at noget stort er på vej
-
Hvordan tolker du det, Pensionisten?
-
Hvilke US-ansatte er der tale om - er det nye og/eller gamle??!
-
rart med fornuftig rebound
-
og ned skal ikke i vinkælderen i dag:)
-
nej...
-
Tirsdagens aktier: Ørsted og Zealand viste fine takter - DSV faldt inden regnskab https://www.proinvestor.com/investornyt/1149115/tirsdagens-aktier-orsted-og-zealand-viste-fine-takter-dsv-faldt-inden-regnskab
-
Nordea løfter kursmålet for Zealand Pharma fra 570 til 764
-
tak @Aps invest
-
@Bullish Nordea har en af de markeds dominerede analytikere på biotek, så burde give en god reaktion op,..men markedet har sine egne veje:)
-
udsnit: Derudover ser banken "en potentielt bedre differentieringsprofil" for vægttabsbehandlingen Survodutide, som Zealand tester sammen med samarbejdspartneren Boehringer Ingelheim.
Det er understøttet af de seneste nyheder fra Boehringer i forskningen inden for behandling af fedtlever, eller MASH .
Nordea ser nu en topsalgsmulighed for Survodutide på omkring 12 mia. dollar mod et tidligere skøn på 7,5 mia. dollar.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind